100 Abbott Park Road
About Abbott Laboratories
1447 articles with Abbott Laboratories
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States.
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
Abbott announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation, that demonstrate long-term benefits of the device in patients battling heart failure.
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
Abbott announced late-breaking data for the TriClip™ transcatheter edge-to-edge repair system, a first-of-its-kind minimally invasive device designed specifically for tricuspid heart valve repair.
Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices
Abbott (NYSE: ABT) today announced late-breaking data for its next-generation Navitor™ transcatheter aortic valve implantation (TAVI) system.
Abbott Declares 397th Consecutive Quarterly Dividend
The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.
Abbott to Acquire Cardiovascular Systems, Inc.
Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
The mixed reality technology is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood.
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
Abbott (NYSE: ABT) today announced that its FreeStyle Libre® 3 sensor is now compatible with the mylife™ Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data.
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
This marks the company's 51st consecutive year of dividend growth. It will be the 396th consecutive quarterly dividend to be paid by Abbott since 1924.
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous glucose monitoring technology as the "Best Medical Technology" of the last 50 years during its Prix Galien Golden Jubilee Awards ceremony on Oct. 27 in New York City.
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period").
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
Abbott announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases.
Abbott Declares 395th Consecutive Quarterly Dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share.
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
Abbott announced three-year data showing the positive impact of the Amplatzer Piccolo™ Occluder on treating babies with a potentially life-threatening hole in the heart known as a patent ductus arteriosus.
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.